Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC

INTRODUCTION: In patients with NSCLC harboring oncogenic ALK or ROS1 rearrangements, tyrosine kinase inhibitors have yielded high response rates and improvements in progression-free survival compared with cytotoxic chemotherapy; however, acquired resistance eventually develops. In preclinical models...

Descripción completa

Detalles Bibliográficos
Autores principales: Lara, Matthew S., Gubens, Matthew A., Bacaltos, Bianca, Daran, Lea, Lim, Steffany L., Li, Tianhong, Gandara, David R., Bivona, Trever G., Riess, Jonathan W., Blakely, Collin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761844/
https://www.ncbi.nlm.nih.gov/pubmed/36545322
http://dx.doi.org/10.1016/j.jtocrr.2022.100436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761844/
https://www.ncbi.nlm.nih.gov/pubmed/36545322
http://dx.doi.org/10.1016/j.jtocrr.2022.100436

Ejemplares similares